An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

  Back

https://uploads-ssl.webflow.com/65dc93ef0a9b2f3705d0635e/6602af4915e8092cc91b3b95_Oncotarget_better_res.png